Cargando…
Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588961/ https://www.ncbi.nlm.nih.gov/pubmed/31201196 http://dx.doi.org/10.1136/bmjopen-2018-022051corr2 |
| _version_ | 1783429316479025152 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6588961 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65889612019-07-05 Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK BMJ Open Correction BMJ Publishing Group 2019-06-14 /pmc/articles/PMC6588961/ /pubmed/31201196 http://dx.doi.org/10.1136/bmjopen-2018-022051corr2 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correction Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK |
| title | Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
|
| title_full | Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
|
| title_fullStr | Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
|
| title_full_unstemmed | Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
|
| title_short | Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
|
| title_sort | correction: real-world effectiveness evaluation of budesonide/formoterol spiromax for the management of asthma and chronic obstructive pulmonary disease in the uk |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588961/ https://www.ncbi.nlm.nih.gov/pubmed/31201196 http://dx.doi.org/10.1136/bmjopen-2018-022051corr2 |